AGL 6.75 Decreased By ▼ -0.05 (-0.74%)
ANL 9.35 Increased By ▲ 0.13 (1.41%)
AVN 77.01 Increased By ▲ 2.81 (3.79%)
BOP 5.40 Decreased By ▼ -0.03 (-0.55%)
CNERGY 4.93 Increased By ▲ 0.04 (0.82%)
EFERT 78.20 Increased By ▲ 0.20 (0.26%)
EPCL 55.40 Increased By ▲ 0.70 (1.28%)
FCCL 15.21 Increased By ▲ 0.28 (1.88%)
FFL 6.33 Decreased By ▼ -0.01 (-0.16%)
FLYNG 7.18 Increased By ▲ 0.06 (0.84%)
GGGL 10.52 Decreased By ▼ -0.04 (-0.38%)
GGL 16.46 Increased By ▲ 0.03 (0.18%)
GTECH 8.20 Decreased By ▼ -0.01 (-0.12%)
HUMNL 6.40 Increased By ▲ 0.05 (0.79%)
KEL 2.95 No Change ▼ 0.00 (0%)
LOTCHEM 28.49 Decreased By ▼ -0.11 (-0.38%)
MLCF 27.98 Increased By ▲ 0.18 (0.65%)
OGDC 75.29 Decreased By ▼ -0.01 (-0.01%)
PAEL 15.88 Increased By ▲ 0.08 (0.51%)
PIBTL 5.62 Increased By ▲ 0.02 (0.36%)
PRL 17.06 Decreased By ▼ -0.16 (-0.93%)
SILK 1.06 No Change ▼ 0.00 (0%)
TELE 10.61 Increased By ▲ 0.31 (3.01%)
TPL 8.04 Increased By ▲ 0.04 (0.5%)
TPLP 21.00 Increased By ▲ 0.20 (0.96%)
TREET 22.95 Increased By ▲ 0.35 (1.55%)
TRG 133.20 Increased By ▲ 4.35 (3.38%)
UNITY 23.02 Increased By ▲ 0.52 (2.31%)
WAVES 11.60 Decreased By ▼ -0.40 (-3.33%)
WTL 1.13 No Change ▼ 0.00 (0%)
BR100 4,134 Increased By 34.5 (0.84%)
BR30 15,712 Increased By 179.1 (1.15%)
KSE100 41,316 Increased By 187.2 (0.46%)
KSE30 15,467 Increased By 130.4 (0.85%)
Business & Finance

Moderna plans trial of altered COVID-19 vaccine booster to address South Africa variant

  • The company said the vaccine did not see any impact from the U.K. variant - which has been shown to be more transmissible - in the tests.
  • The company said it plans to publish data from its tests against the South African and U.K. variants on the website.
Published January 25, 2021
Follow us

Moderna plans trial of altered COVID-19 vaccine booster to address South Africa variant

Moderna said on Monday it plans to start clinical trials of an altered booster version of its COVID-19 vaccine aimed at the South African variant after tests showed its authorised vaccine may produce a diminished antibody response.

It will also test an additional booster shot of its authorised vaccine in trials to see if it boosts antibody reaction against the South Africa variant. The current regimen is for two shots four weeks apart.

The company said in a press release that it was being cautious and that the two-dose regimen of the vaccine was still expected to be protective against the South African and other variants detected to date.

The company said the vaccine did not see any impact from the U.K. variant - which has been shown to be more transmissible - in the tests.

The company said it plans to publish data from its tests against the South African and U.K. variants on the website bioRxiv.

Comments

Comments are closed.